
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) with one indication being first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
In this session, Dr. Marc Denis discusses clinical cases where EGFR-positive NSCLC patients have developed resistance to osimertinib during treatment. He details how molecular testing is deployed again to determine the mechanism of resistance, and the possible treatment outcomes for patients based on the results of that testing.